INKT — MiNK Therapeutics, Inc.

Summary of MiNK Therapeutics, Inc. Q3 2025 Earnings Call

1. Key Financial Results and Metrics

• Cash Position: Ended Q3 2025 with a cash balance of $14.3 million, with an additional $1.2 million raised post-quarter through an at-the-market sales agreement.
• Net Loss: Reported a net loss of $2.9 million ($0.65 per share) for Q3 2025, compared to a net loss of $1.8 million ($0.46 per share) in Q3 2024. For the nine months ended September 30, 2025, the net loss was $9.9 million ($2.39 per share), up from $8.3 million ($2.24 per share) in the same period of 2024.

2. Strategic Updates and Business Highlights

• Clinical Advancements: Presented promising clinical data for AGENT-797, an allo, off-the-shelf iNKT cell therapy, showing a median overall survival of approximately 23 months in patients with relapsed or refractory solid tumors, significantly exceeding expectations for this patient population.
• Partnerships: Established a strategic partnership with the University of Wisconsin Carbone Cancer Center to advance INKT therapy for immune reconstitution following stem cell transplantation, supported by public-private grants.
• Leadership Changes: Welcomed Dr. John Holcomb to the Board and highlighted Dr. Terese Hammond's leadership in advancing the INKT platform into broader inflammatory diseases.

3. Forward Guidance and Outlook

• Clinical Trials: Preparing for a global Phase 2 trial in acute pulmonary dysfunction and a Phase I study for graft-versus-host disease (GVHD), with expectations to launch the pulmonary trial by early Q1 2026.
• Expansion Plans: Plans to expand the combination therapy cohort for AGENT-797 based on positive early results, with potential Phase 2 studies in specific cancer types.
• Financial Strategy: Aiming to leverage partnerships and grants to minimize capital impact while advancing clinical programs, with a focus on maintaining a strong cash runway through 2026.

4. Bad News, Challenges, or Points of Concern

• Increasing Losses: The net loss has increased year-over-year, raising concerns about the sustainability of operations without additional funding.
• Market Competition: The competitive landscape in cell therapy and oncology remains intense, with the need for MiNK to differentiate its offerings effectively.
• Regulatory Risks: As clinical trials progress, there are inherent risks related to regulatory approvals and the potential for delays or failures in clinical development.

5. Notable Q&A Insights

• Combination Therapy Expansion: Management indicated plans to expand the combination therapy cohort for AGENT-797, particularly in patients who have failed PD-1 therapy, with a focus on achieving rapid development pathways.
• Pulmonary Disease Trial Timing: The launch of the severe pulmonary disease trial is expected imminently, with the first patient to be dosed by early Q1 2026.
• Endpoints and Patient Enrollment: In the GVHD trial, endpoints will include the presence or absence of GVHD at day 100, with a goal to significantly reduce the incidence compared to current standards of care. The pulmonary trial will focus on well-established endpoints like 28-day mortality and ventilator-free days.

This summary encapsulates the key aspects of MiNK Therapeutics' Q3 2025 earnings call, highlighting both the positive advancements and the challenges faced by the company.